Research map: Application of Theranostics in Thyroid Cancer Management

Back to the article

Papers in this map

  1. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer · Bryan R. Haugen · 2015 · 16725 citations · Cited by this paper
  2. Medical treatments for obesity: what does the future have in store? · 2026 · Related
  3. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors · Richard L. Wahl · 2009 · 3834 citations · Cited by this paper
  4. Inter-individual variation in gastric emptying is related to GLP-1 response to intraduodenal glucose exposure in health · 2026 · Related
  5. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma · Samuel A. Wells · 2015 · 2458 citations · Cited by this paper
  6. Low serum testosterone concentrations predict incident frailty in men with HIV · 2026 · Related
  7. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours · John J. Zaknun · 2013 · 828 citations · Cited by this paper
  8. Treatment of severe hypertriglyceridemia: a new era dawns · 2026 · Related
  9. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer · Matthew David Ringel · 2025 · 661 citations · Cited by this paper
  10. Impairment in the hypothalamic–pituitary–gonadal axis in males with medullary thyroid carcinoma treated with selpercatinib · 2026 · Related
  11. LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN · E. P. Krenning · 1989 · 628 citations · Cited by this paper
  12. Is the diagnosis of Cushing disease moving beyond bilateral inferior petrosal sinus sampling? · 2026 · Related
  13. Cancer-associated fibroblasts: from basic science to anticancer therapy · Dakai Yang · 2023 · 549 citations · Cited by this paper
  14. Prospective evaluation of the effect of stopping estrogen-containing contraceptives on serum CBG and cortisol levels · 2026 · Related
  15. Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience · Roelf Valkema · 2002 · 436 citations · Cited by this paper
  16. Consensus on Biomarker Utility for ACTH-Dependent Cushing’s Syndrome: A Pituitary Society Modified Delphi Panel · 2026 · Related
  17. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). · Yogesh Patel · 1994 · 348 citations · Cited by this paper
  18. Melanocortin-4 receptor regulation of endocrine axes and clinical effects of setmelanotide · 2026 · Related
  19. Radiotherapy with a Radiolabeled Somatostatin Analogue, [ 111 In‐DTPA‐ d ‐Phe 1 ]‐Octreotide · Eric P. Krenning · 1994 · 315 citations · Cited by this paper
  20. Approach to the patient with elevated lipoprotein(a) · 2026 · Related
  21. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals · Damian Wild · 2003 · 306 citations · Cited by this paper
  22. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements · Brian J. Burkett · 2023 · 212 citations · Cited by this paper
  23. Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial · Fabienne Iten · 2007 · 170 citations · Cited by this paper
  24. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials · Loredana Gabriela Marcu · 2018 · 147 citations · Cited by this paper
  25. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma · Luca Giovanella · 2019 · 141 citations · Cited by this paper
  26. Cholecystokinin‐B (CCK‐B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK‐B receptor expressing malignancies · Martin Béhé · 2002 · 125 citations · Cited by this paper
  27. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients · Jingjing Zhang · 2018 · 124 citations · Cited by this paper
  28. Design and in Vitro Characterization of Highly sst 2 -Selective Somatostatin Antagonists Suitable for Radiotargeting · Renzo Cescato · 2008 · 115 citations · Cited by this paper
  29. Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study · Hao Fu · 2023 · 114 citations · Cited by this paper
  30. 68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours · Rohini Sharma · 2019 · 109 citations · Cited by this paper
  31. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors · Jingjing Zhang · 2018 · 100 citations · Cited by this paper
  32. PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics · Andrey Bychkov · 2017 · 96 citations · Cited by this paper
  33. Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study · Christof Rottenburger · 2019 · 92 citations · Cited by this paper
  34. 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617 · Lisa H. de Vries · 2020 · 89 citations · Cited by this paper
  35. Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics · Marcel Martin · 2023 · 78 citations · Cited by this paper
  36. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review · Zohreh Maghsoomi · 2021 · 57 citations · Cited by this paper
  37. Detection of Synchronous Primary Malignancies with 68 Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients · Medhat M. A. Osman · 2017 · 53 citations · Cited by this paper
  38. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls · Carolien M. Beukhof · 2019 · 53 citations · Cited by this paper
  39. 68 Ga-DOTA-RGD 2 Positron Emission Tomography/Computed Tomography in Radioiodine Refractory Thyroid Cancer: Prospective Comparison of Diagnostic Accuracy with 18 F-FDG Positron Emission Tomography/Computed Tomography and Evaluation Toward Potential Theranostics · Ashwin Singh Parihar · 2019 · 52 citations · Cited by this paper

Source: OpenAlex (CC0)